{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:06:44Z","timestamp":1793232404912,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.eururo.2024.09.036","type":"journal-article","created":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T00:53:21Z","timestamp":1729385601000},"page":"125-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers"],"prefix":"10.1016","volume":"87","author":[{"given":"Martina","family":"Sollini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.09.036_b0005","doi-asserted-by":"crossref","unstructured":"Kirienko M, Gelardi F, Fiz F, et al. Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication. Eur J Nucl Med Mol Imaging. In press. https:\/\/doi.org\/10.1007\/s00259-024-06882-9.","DOI":"10.1007\/s00259-024-06882-9"},{"key":"10.1016\/j.eururo.2024.09.036_b0010","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1007\/s00259-022-05768-y","article-title":"Things are because we see them (O. Wilde): new radiopharmaceuticals for nuclear medicine imaging","volume":"49","author":"Sollini","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.036_b0015","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1053\/j.semnuclmed.2021.06.013","article-title":"PET\/CT limitations and pitfalls in urogenital cancers","volume":"51","author":"Vasireddi","year":"2021","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.983023","article-title":"An overview of radiolabeled amino acid tracers in oncologic imaging","volume":"13","author":"Jain","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2024.09.036_b0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.semnuclmed.2023.07.001","article-title":"PSMA PET\/CT for primary staging of prostate cancer\u2014an updated overview","volume":"54","author":"Jochumsen","year":"2024","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0030","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1148\/rg.2018170108","article-title":"Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls","volume":"38","author":"Hofman","year":"2018","journal-title":"Radiographics"},{"key":"10.1016\/j.eururo.2024.09.036_b0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s12149-024-01904-w","article-title":"Role of PSMA-targeted PET-CT in renal cell carcinoma: a systematic review and meta-analysis","volume":"38","author":"Singhal","year":"2024","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0040","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2023.03.001","article-title":"Next generation radiotheranostics promoting precision medicine","volume":"34","author":"Pomykala","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.036_b0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semradonc.2020.07.006","article-title":"Radiopharmaceutical chemistry and drug development\u2014what\u2019s changed?","volume":"31","author":"Kunos","year":"2021","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.eururo.2024.09.036_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph14020167","article-title":"Advances in development of radiometal labeled amino acid-based compounds for cancer imaging and diagnostics","volume":"14","author":"Mikulova","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.eururo.2024.09.036_b0055","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2024.09.036_b0060","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jebm.12141","article-title":"The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review","volume":"8","author":"Zeng","year":"2015","journal-title":"J Evid Based Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0065","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00259-021-05580-0","article-title":"The impact of drainage pathways on the detection of nodal metastases in prostate cancer: a phase II randomized comparison of intratumoral vs intraprostatic tracer injection for sentinel node detection","volume":"49","author":"Wit","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.036_b0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.eururo.2022.03.002","article-title":"Robot-assisted prostate-specific membrane antigen-radioguided salvage surgery in recurrent prostate cancer using a DROP-IN gamma probe: the first prospective feasibility study","volume":"82","author":"de Barros","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.036_b0075","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s12149-022-01741-9","article-title":"99mTc-PSMA targeted robot-assisted radioguided surgery during radical prostatectomy and extended lymph node dissection of prostate cancer patients","volume":"36","author":"Y\u0131lmaz","year":"2022","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0080","first-page":"1659","article-title":"Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer","volume":"63","author":"Gondoputro","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0085","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.eururo.2022.06.002","volume":"82","author":"Gandaglia","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.036_b0090","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.3390\/cancers15061631","article-title":"Phase I trial of [99mTc]Tc-maSSS-PEG2-RM26, a bombesin analogue antagonistic to gastrin-releasing peptide receptors (GRPRs), for SPECT imaging of GRPR expression in malignant tumors","volume":"15","author":"Chernov","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2024.09.036_b0095","doi-asserted-by":"crossref","first-page":"15993","DOI":"10.1038\/s41598-022-20280-x","article-title":"Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT\/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial","volume":"12","author":"Zhang","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2024.09.036_b0100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5603\/NMR.2021.0018","article-title":"SPECT-CT imaging with [99mTc]PSMA-T4 in patients with recurrent prostate cancer","volume":"24","author":"Sergieva","year":"2021","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"10.1016\/j.eururo.2024.09.036_b0105","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1097\/RLU.0000000000003410","article-title":"99mTc-PSMA SPECT\/CT versus 68Ga-PSMA PET\/CT in the evaluation of metastatic prostate cancer","volume":"46","author":"Fallahi","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0110","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/MNM.0000000000001361","article-title":"Comparison of the diagnostic utility of 99mTc-PSMA scintigraphy versus 68Ga-PSMA-11 PET\/CT in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate-specific membrane antigen imaging modality","volume":"42","author":"Singh","year":"2021","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.eururo.2024.09.036_b0115","first-page":"1","article-title":"Direct comparison of 99mTc-PSMA SPECT\/CT and 68Ga-PSMA PET\/CT in patients with prostate cancer","volume":"8","author":"Albalooshi","year":"2020","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"10.1016\/j.eururo.2024.09.036_b0120","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00259-020-04883-y","article-title":"A microdose clinical trial to evaluate [18F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer","volume":"48","author":"Lee","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.036_b0125","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3348\/kjr.2022.0176","article-title":"Phase I clinical trial of prostate-specific membrane antigen-targeting 68Ga-NGUL PET\/CT in healthy volunteers and patients with prostate cancer","volume":"23","author":"Suh","year":"2022","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.eururo.2024.09.036_b0130","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2967\/jnumed.118.220715","article-title":"Phase I study of CTT1057, an 18F-labeled imaging agent with phosphoramidate core targeting prostate-specific membrane antigen in prostate cancer","volume":"60","author":"Behr","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0135","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s11307-019-01421-7","article-title":"[68Ga]Ga-P16-093 as a PSMA-targeted PET radiopharmaceutical for detection of cancer: initial evaluation and comparison with [68Ga]Ga-PSMA-11 in prostate cancer patients presenting with biochemical recurrence","volume":"22","author":"Green","year":"2020","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.eururo.2024.09.036_b0140","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1007\/s00259-023-06283-4","article-title":"A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET\/CT in patients with primary prostate cancer","volume":"50","author":"Wang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.036_b0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41824-022-00161-2","article-title":"18F-JK-PSMA-7 PET\/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study","volume":"7","author":"Vierasu","year":"2023","journal-title":"Eur J Hybrid Imaging"},{"key":"10.1016\/j.eururo.2024.09.036_b0150","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00330-022-08982-2","article-title":"Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I\/II study","volume":"33","author":"Beheshti","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2024.09.036_b0155","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2967\/jnumed.120.258814","article-title":"GRPr antagonist 68Ga-SB3 PET\/CT imaging of primary prostate cancer in therapy-na\u00efve patients","volume":"62","author":"Bakker","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0160","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.euo.2018.08.011","article-title":"Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography\/computed tomography imaging of newly diagnosed prostate cancer","volume":"2","author":"Touijer","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.09.036_b0165","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2967\/jnumed.122.263971","article-title":"Correlation of 68Ga-RM2 PET with postsurgery histopathology findings in patients with newly diagnosed intermediate- or high-risk prostate cancer","volume":"63","author":"Duan","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0170","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2967\/jnumed.122.263889","article-title":"Comparison of 68Ga-PSMA-617 PET\/CT and 68Ga-RM2 PET\/CT in patients with localized prostate cancer who are candidates for radical prostatectomy: a prospective, single-arm, single-center, phase II study","volume":"64","author":"Schollhammer","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0175","doi-asserted-by":"crossref","first-page":"744","DOI":"10.2967\/jnumed.122.264448","article-title":"A pilot study of 68Ga-PSMA11 and 68Ga-RM2 PET\/MRI for biopsy guidance in patients with suspected prostate cancer","volume":"64","author":"Duan","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0180","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2967\/jnumed.122.264783","article-title":"A pilot study of 68Ga-PSMA11 and 68Ga-RM2 PET\/MRI for evaluation of prostate cancer response to high-intensity focused ultrasound therapy","volume":"64","author":"Duan","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0185","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/cancers14020334","article-title":"68Ga-PSMA and 68Ga-DOTA-RM2 PET\/MRI in recurrent prostate cancer: diagnostic performance and association with clinical and histopathological data","volume":"14","author":"Mapelli","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2024.09.036_b0190","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00259-023-06483-y","article-title":"Diagnostic accuracy of fully hybrid [68Ga]Ga-PSMA-11 PET\/MRI and [68Ga]Ga-RM2 PET\/MRI in patients with biochemically recurrent prostate cancer: a prospective single-center phase II clinical trial","volume":"51","author":"Ghezzo","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.036_b0195","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.7150\/thno.49422","article-title":"First clinical study of a pegylated diabody 124I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers","volume":"10","author":"Scott","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.eururo.2024.09.036_b0200","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1021\/acs.molpharmaceut.9b00326","article-title":"Pharmacokinetics and biodistribution of a [89Zr]Zr-DFO-MSTP2109A anti-STEAP1 antibody in metastatic castration-resistant prostate cancer patients","volume":"16","author":"O\u2019Donoghue","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.eururo.2024.09.036_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2020.04.002","article-title":"Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [68Ga]Ga-P15-041, a gallium-68 labeled bisphosphonate, from first-in-human studies","volume":"86\u201387","author":"Doot","year":"2020","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.eururo.2024.09.036_b0210","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2967\/jnumed.120.248120","article-title":"Urokinase-type plasminogen activator receptor (uPAR) PET\/MRI of prostate cancer for noninvasive evaluation of aggressiveness: comparison with Gleason score in a prospective phase 2 clinical trial","volume":"62","author":"Fosb\u00f8l","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0215","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2967\/jnumed.118.220111","article-title":"Assessment of simplified methods for quantification of 18F-FDHT uptake in patients with metastatic castration-resistant prostate cancer","volume":"60","author":"Kramer","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0220","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2967\/jnumed.122.264981","article-title":"Consecutive prostate-specific membrane antigen (PSMA) and antigen receptor (AR) PET imaging shows positive correlation with AR and PSMA protein expression in primary hormone-na\u00efve prostate cancer","volume":"64","author":"al Jalali","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0225","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12149-018-1312-6","article-title":"Phase I\/IIa PET imaging study with 89 zirconium labeled anti-PSMA minibody for urological malignancies","volume":"33","author":"Joraku","year":"2019","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0230","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s11307-022-01720-6","article-title":"Preliminary evaluation of 68Ga-P16-093, a PET radiotracer targeting prostate-specific membrane antigen in prostate cancer","volume":"24","author":"Lee","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.eururo.2024.09.036_b0235","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/RLU.0000000000003658","article-title":"Efficacy and safety of the 64Cu(II)Cl2 PET\/CT for urological malignancies: phase IIa clinical study","volume":"46","author":"Mascia","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0240","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2967\/jnumed.120.245530","article-title":"A microdosing study with 99mTc-PHC-102 for the SPECT\/CT imaging of primary and metastatic lesions in renal cell carcinoma patients","volume":"62","author":"Kulterer","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0245","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00259-022-06101-3","article-title":"Head-to-head comparison of [68Ga]Ga-P16-093 and 2-[18F]FDG PET\/CT in patients with clear cell renal cell carcinoma: a pilot study","volume":"50","author":"Wang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.036_b0250","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00259-020-05022-3","article-title":"Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC","volume":"48","author":"Kramer","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.036_b0255","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/cncr.32072","article-title":"Phase 1\/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer","volume":"125","author":"Tagawa","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.09.036_b0260","doi-asserted-by":"crossref","first-page":"848.e9","DOI":"10.1016\/j.urolonc.2020.05.028","article-title":"Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer","volume":"38","author":"Batra","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.09.036_b0265","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.23.00573","article-title":"Prostate-specific membrane antigen-targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: a phase I dose-escalation study of 225Ac-J591","volume":"42","author":"Tagawa","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.036_b0270","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.euo.2022.09.002","article-title":"Neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: a single-arm phase 1 trial","volume":"6","author":"Golan","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.09.036_b0275","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3348\/kjr.2023.0656","article-title":"Dosimetric analysis of a phase I study of PSMA-targeting radiopharmaceutical therapy with [177Lu]Ludotadipep in patients with metastatic castration-resistant prostate cancer","volume":"25","author":"Ha","year":"2024","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.eururo.2024.09.036_b0280","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00259-023-06470-3","article-title":"A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer","volume":"51","author":"Zang","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.036_b0285","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.7150\/thno.48107","article-title":"Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients","volume":"10","author":"Yadav","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.eururo.2024.09.036_b0290","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/RLU.0000000000004818","article-title":"A phase 1, open-label, dose-ascending study to evaluate the safety and tolerability of the therapeutic radiopharmaceutical 131i-MIP-1095 for the treatment of metastatic castration-resistant prostate cancer","volume":"48","author":"Laccetti","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0295","article-title":"Commercial and business aspects of alpha radioligand therapeutics","volume":"9","author":"Ostuni","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.eururo.2024.09.036_b0300","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2967\/jnumed.123.267175","article-title":"First-in-human safety, imaging, and dosimetry of a carbonic anhydrase IX\u2013targeting peptide, [68Ga]Ga-DPI-4452, in patients with clear cell renal cell carcinoma","volume":"65","author":"Hofman","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0305","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1007\/s00259-023-06248-7","article-title":"Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma","volume":"50","author":"Zhu","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.036_b0310","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.trecan.2023.07.011","article-title":"Genitourinary cancer neoadjuvant therapies: current and future approaches","volume":"9","author":"Nair","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.eururo.2024.09.036_b0315","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.036_b0320","unstructured":"Mottet N, Bellmunt J, Briers E, et al. EAU \u2013 ESTRO \u2013 ESUR \u2013 SIOG guidelines on prostate cancer. Arnhem, The Netherlands: EAU Guidelines Office; 2020."},{"key":"10.1016\/j.eururo.2024.09.036_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101450","article-title":"Advances in PSMA theranostics","volume":"22","author":"Jeitner","year":"2022","journal-title":"Transl Oncol"},{"key":"10.1016\/j.eururo.2024.09.036_b0330","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12210-020-00900-2","article-title":"The five \u201cw\u201ds and \u201chow\u201d of targeted alpha therapy: why? who? what? where? when? and how?","volume":"31","author":"Sollini","year":"2020","journal-title":"Rendiconti Lincei Scienze Fisiche e Naturali"},{"key":"10.1016\/j.eururo.2024.09.036_b0335","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/ph15010013","article-title":"Expanding theranostic radiopharmaceuticals for tumor diagnosis and therapy","volume":"15","author":"Barca","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.eururo.2024.09.036_b0340","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.2967\/jnumed.122.265291","article-title":"161Tb-PSMA Radioligand therapy: first-in-humans SPECT\/CT imaging","volume":"64","author":"Al-Ibraheem","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0345","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2967\/jnumed.123.267189","article-title":"First-in-human 212Pb-PSMA\u2013targeted \u03b1-therapy SPECT\/CT imaging in a patient with metastatic castration-resistant prostate cancer","volume":"65","author":"Griffiths","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0350","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/14737140.2023.2223987","article-title":"What\u2019s to come in PSMA therapies and diagnostics: a summary of clinical trials involving PSMA radioligand-based therapeutic and\/or diagnostic approaches with active recruitment","volume":"23","author":"Dawson","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.eururo.2024.09.036_b0355","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7150\/ntno.64141","article-title":"Radiotheranostics\u2014precision medicine in nuclear medicine and molecular imaging","volume":"6","author":"Duan","year":"2022","journal-title":"Nanotheranostics"},{"key":"10.1016\/j.eururo.2024.09.036_b0360","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1007\/s00259-022-05921-7","article-title":"Present and future of target therapies and theranostics: refining traditions and exploring new frontiers-highlights from Annals of Nuclear Medicine 2021","volume":"49","author":"Pini","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.036_b0365","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3390\/jcm11102738","article-title":"Update of PSMA theranostics in prostate cancer: current applications and future trends","volume":"11","author":"Kaewput","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0370","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3390\/cancers16101926","article-title":"Update on renal cell carcinoma diagnosis with novel imaging approaches","volume":"16","author":"Bellin","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2024.09.036_b0375","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2967\/jnumed.124.267417","article-title":"Utility of PSMA PET\/CT in staging and restaging of renal cell carcinoma: a systematic review and metaanalysis","volume":"65","author":"Sadaghiani","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0380","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cpet.2024.03.006","article-title":"Alpha and beta radiation for theragnostics","volume":"19","author":"Song","year":"2024","journal-title":"PET Clin"},{"key":"10.1016\/j.eururo.2024.09.036_b0385","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.3390\/cancers15123133","article-title":"Innovation in radionuclide therapy for the treatment of prostate cancers: radiochemical perspective and recent therapeutic practices","volume":"15","author":"Deshayes","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2024.09.036_b0390","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0395","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.036_b0400","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2967\/jnumed.123.267260","article-title":"A systematic review on the diagnostic value of fibroblast activation protein inhibitor PET\/CT in genitourinary cancers","volume":"65","author":"Hagens","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.036_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2023.102769","article-title":"Generative AI for graph-based drug design: recent advances and the way forward","volume":"84","author":"Garg","year":"2024","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.eururo.2024.09.036_b0410","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00259-020-05073-6","article-title":"Climbing the steps of the evidence-based medicine pyramid: highlights from Annals of Nuclear Medicine 2019","volume":"48","author":"Gelardi","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824026411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824026411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T20:41:42Z","timestamp":1737664902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824026411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0302283824026411"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.09.036","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.09.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}